Insulin aspart
- Generic Name
- Insulin aspart
- Brand Names
- Fiasp, Novolog, Novolog Mix, Novomix, Novorapid, Novorapid Penfill, Ryzodeg, Truvelog Mix 30, Kirsty (previously Kixelle), NovoRapid, Insulin aspart Sanofi, NovoMix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 116094-23-6
- Unique Ingredient Identifier
- D933668QVX
- Background
Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM), Hyperglycemia during critical illness
- Associated Therapies
- -
Comparison of Antibody Levels in Children and Adolescents After Initiation of Insulin Therapy by Either Insulin Aspart or Soluble Human Insulin
- Conditions
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 74
- Registration Number
- NCT00410033
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Linköping, Sweden
Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes
- Conditions
- First Posted Date
- 2006-08-17
- Last Posted Date
- 2016-12-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 419
- Registration Number
- NCT00365170
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Worcester, United Kingdom
Bioavailability of Insulin Administered in Duodenum
- Conditions
- First Posted Date
- 2006-07-19
- Last Posted Date
- 2007-04-25
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 12
- Registration Number
- NCT00353990
- Locations
- 🇩🇰
Medical Department M, Aarhus, Denmark
Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 618
- Registration Number
- NCT00331604
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2006-05-05
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 596
- Registration Number
- NCT00322257
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Vancouver, Canada
Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes
- Conditions
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 325
- Registration Number
- NCT00312104
- Locations
- 🇿🇦
Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa
Comparison of Efficacy and Safety of Insulin Detemir and NPH Insulin in Children and Adolescents With Type 1 Diabetes
- Conditions
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 347
- Registration Number
- NCT00312156
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Stirling, United Kingdom
Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes
- Conditions
- First Posted Date
- 2006-01-26
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 79
- Registration Number
- NCT00282451
- Locations
- 🇸🇦
Novo Nordisk Investigational Site, Riyadh, Saudi Arabia
Efficacy and Safety of a Fixed or a Flexible Supplementary Insulin Therapy in Type 2 Diabetes
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2014-11-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 373
- Registration Number
- NCT00274274
Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-12-21
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 9
- Registration Number
- NCT00267683
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.